杜氏肌营养不良外显子2重复所致抗肌萎缩蛋白病的表型谱
该回顾性观察研究分析了United Dystrophinopathy Project和意大利DMD网络数据库中66例DMD外显子2重复(Dup2)个体,将其分为DMD、中间型肌营养不良(IMD)或BMD表型。结果显示61%为DMD、9%为IMD、30%为BMD,Dup2 DMD患者丧失行走年龄与无Dup2 DMD历史对照显著不同(p < 0.001),部分患者病程较轻,提示IRES激活作为分子机制的可能性。
要点
- 66例Dup2个体中61%为DMD、9%为IMD、30%为BMD。
- Dup2 DMD患者丧失行走年龄与无Dup2 DMD历史对照差异显著(p < 0.001)。
- 部分Dup2患者病程较无Dup2 DMD对照轻,提示IRES激活可能。
核心结论
- 部分Dup2患者病程较无Dup2 DMD对照轻,延长行走与皮质类固醇使用提示IRES激活作为分子机制的可能性;随着Dup2靶向治疗进入临床应用,该信息对解读新疗法疗效至关重要。
研究设计与样本
- 回顾性观察研究,分析United Dystrophinopathy Project(UDP)和意大利DMD网络大型基因型-表型数据库数据。
- 共纳入66例DMD外显子2重复(Dup2)个体(UDP=40,意大利=26),分为DMD、IMD或BMD表型。
- 采用Log-rank检验比较UDP数据库中Dup2与非Dup2对照的丧失行走年龄,以及Dup2中经类固醇治疗与未治疗者的比较。
主要发现
- 66例Dup2个体中61%为DMD、9%为IMD、30%为BMD。
- 末次观察中位年龄15.4岁(四分位距8.79-26.0),75%接受皮质类固醇至少6个月。
- Dup2 DMD患者丧失行走年龄与无Dup2 DMD历史对照差异显著(p < 0.001)。
- 有效肺功能检查有限,但提示用力肺活量典型年龄相关下降延迟;55例有足够心脏数据者中24例有心肌病。
局限性
- 有效肺功能检查有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To describe the phenotypic spectrum of dystrophinopathy in a large cohort of individuals with DMD exon 2 duplications (Dup2), who may be particularly amenable to therapies directed at restoring expression of either full-length dystrophin or nearly full-length dystrophin through utilization of the DMD exon 5 internal ribosome entry site (IRES). METHODS: In this retrospective observational study, we analyzed data from large genotype-phenotype databases (the United Dystrophinopathy Project [UDP] and the Italian DMD network) and classified participants into Duchenne muscular dystrophy (DMD), intermediate muscular dystrophy (IMD), or Becker muscular dystrophy (BMD) phenotypes. Log-rank tests for time-to-event variables were used to compare age at loss of ambulation (LOA) in participants with Dup2 vs controls without Dup2 in the UDP database and for comparisons between steroid-treated vs steroid-naive participants with Dup2. RESULTS: Among 66 participants with Dup2 (UDP = 40, Italy = 26), 61% were classified as DMD, 9% as IMD, and 30% as BMD. Median age at last observation was 15.4 years (interquartile range 8.79-26.0) and 75% had been on corticosteroids for at least 6 months. Age at LOA differed significantly between participants with Dup2 DMD and historical controls without Dup2 DMD (p < 0.001). Valid spirometry was limited but suggested a delay in the typical age-related decline in forced vital capacity and 24 of 55 participants with adequate cardiac data had cardiomyopathy. DISCUSSION: Some patients with Dup2 display a milder disease course than controls without Dup2 DMD, and prolonged ambulation with corticosteroids suggests the potential of IRES activation as a molecular mechanism. As Dup2-targeted therapies reach clinical applications, this information is critical to aid in the interpretation of the efficacy of new treatments.
引用
- Zambon AA, Waldrop MA, Alles R, et al. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021. PMID: 34937785. doi:10.1212/WNL.0000000000013246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。